Genetic polymorphisms of drug metabolism. Possible implications during development

Area of Science:

• Pharmacogenetics
• Drug Metabolism
• Toxicology

Background:

• Genetic polymorphisms significantly alter drug metabolism, affecting both Phase I and Phase II reactions.
• Variations in cytochrome P450 enzymes are linked to increased drug toxicity and cancer development.
• Polymorphisms in detoxification pathways can lead to adverse drug reactions even at standard doses.

Purpose of the Study:

• To explore the role of genetic polymorphisms in drug metabolism.
• To investigate the connection between genetic factors, xenobiotics, and teratogenesis.
• To highlight the significance of pharmacogenetics in understanding drug responses.

Main Methods:

• Analysis of genetic polymorphisms related to drug-metabolizing enzymes.
• Review of literature on cytochrome P450 activity and detoxification pathways.
• Exploration of pharmacogenetic principles in relation to xenobiotics and teratogenesis.

Main Results:

• Genetic variations in drug metabolism pathways are crucial for individual drug responses.
• Cytochrome P450 polymorphisms are key factors in drug toxicity and carcinogenesis.
• Detoxification gene polymorphisms contribute to adverse drug reactions.

Conclusions:

• Pharmacogenetics provides a framework for understanding the interplay between genetics, environmental factors (xenobiotics), and developmental outcomes (teratogenesis).
• Understanding these genetic variations is essential for personalized medicine and preventing adverse drug events.